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ABSTRACT Mycobacterium haemophilum is an emerging pathogen associated with a variety of clinical syndromes, most com-
monly skin infections in immunocompromised individuals.M. haemophilum exhibits a unique requirement for iron supple-
mentation to support its growth in culture, but the basis for this property and how it may shape pathogenesis is unclear. Using a
combination of Illumina, PacBio, and Sanger sequencing, the complete genome sequence ofM. haemophilumwas determined.
Guided by this sequence, experiments were performed to define the basis for the unique growth requirements ofM. haemophi-
lum. We found thatM. haemophilum, unlike many other mycobacteria, is unable to synthesize iron-binding siderophores
known as mycobactins or to utilize ferri-mycobactins to support growth. These differences correlate with the absence of genes
associated with mycobactin synthesis, secretion, and uptake. In agreement with the ability of heme to promote growth, we iden-
tified genes encoding heme uptake machinery. Consistent with its propensity to infect the skin, we show at the whole-genome
level the genetic closeness ofM. haemophilum withMycobacterium leprae, an organism which cannot be cultivated in vitro, and
we identify genes uniquely shared by these organisms. Finally, we identify means to express foreign genes inM. haemophilum.
These data explain the unique culture requirements for this important pathogen, provide a foundation upon which the genome
sequence can be exploited to improve diagnostics and therapeutics, and suggest use ofM. haemophilum as a tool to elucidate
functions of genes shared withM. leprae.
IMPORTANCE Mycobacterium haemophilum is an emerging pathogen with an unknown natural reservoir that exhibits unique
requirements for iron supplementation to grow in vitro. Understanding the basis for this iron requirement is important because
it is fundamental to isolation of the organism from clinical samples and environmental sources. Defining the molecular basis for
M. haemophilium’s growth requirements will also shed new light on mycobacterial strategies to acquire iron and can be ex-
ploited to define how differences in such strategies influence pathogenesis. Here, through a combination of sequencing and ex-
perimental approaches, we explain the basis for the iron requirement. We further demonstrate the genetic closeness ofM. hae-
mophilum andMycobacterium leprae, the causative agent of leprosy which cannot be cultured in vitro, and we demonstrate
methods to genetically manipulateM. haemophilum. These findings pave the way for the use ofM. haemophilum as a model to
elucidate functions of genes shared withM. leprae.
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Mycobacterium haemophilum is a slow-growing acid-fast bac-terium of the nontuberculous mycobacteria group that pre-
fers a lower temperature for growth (30°C to 32°C) and requires
iron supplementation, typically either hemin or high concentra-
tions of ferric ammonium citrate, for its growth (1–3). Like other
mycobacterial species that grow optimally at lower temperatures,
such as Mycobacterium marinum and Mycobacterium ulcerans,
M. haemophilum is most associated with cutaneous infections of
the extremities (1, 4). Less common clinical manifestations of
M. haemophilum infection include skeletal infections, such as os-
teomyelitis and septic arthritis, pulmonary infections, ophthal-
mologic involvement, and disseminated disease (1, 5–11). These
cutaneous and extracutaneous manifestations occur primarily in
the setting of severe immune compromise (12). Some case reports
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have also described a leprosy-like presentation ofM.haemophilum
in immunocompromised individuals (13, 14). M. haemophilum
has also been reported to cause cervicofacial lymphadenitis in im-
munocompetent children (15) and adults (16).
Infection with M. haemophilum occurs worldwide and, al-
though it has been until now an infrequently isolated pathogen,
the incidence appears to be rising since its initial discovery in 1978
(2). This likely reflects the emergence of severe immune compro-
mise due to HIV/AIDS or in the settings of bone marrow/solid
organ transplantation, hematologic malignancy, or treatment
with disease-modifying agents for rheumatologic disorders (8, 12,
17–22), all of which predispose to infection with this opportunis-
tic pathogen. At present there is no standardized protocol for in
vitro susceptibility testing (1), although recommendations for a
disk agar elution method for M. haemophilum are included in a
recent Clinical and Laboratory Standards Institute (CLSI) docu-
ment (23). Further, it is unknown how predictive the results are of
clinical outcomes. Optimal treatment regimens also remain un-
defined (1); however, there is a general consensus that patients
should receive a combination of agents that appear to be active in
vitro, such as clarithromycin, ciprofloxacin, and a rifamycin, for a
prolonged duration (~12 to 24 months) which is tailored to the
individual’s presentation and degree of immune compromise (1,
12, 24, 25). For immunocompetent patients with lymph node in-
volvement, surgical excision may be sufficient (1, 12). The natural
habitat/reservoir of M. haemophilum as well as its mode of trans-
mission also remain poorly defined. While many nontuberculous
mycobacteria are found in soil and aquatic habitats, attempts to
recover M. haemophilum from environmental samples have often
proven unsuccessful, although this may be attributed in part to the
slow growth of the organism and its fastidious growth require-
ments (1).
Very little genetic information has been available for M. hae-
mophilum. This limits understanding of its unique growth re-
quirements and how these properties shape its pathogenesis. We
therefore determined the complete genome sequence of the
M. haemophilum DSM 44634 type strain and performed accom-
panying experiments that implicated the absence of mycobactin
synthesis machinery, which in other mycobacteria plays a critical
role in iron acquisition, as a major factor in the iron dependence of
this organism. Further analysis demonstrated a close evolutionary
relationship with Mycobacterium leprae and identified both ge-
netic features conserved with other mycobacteria and also unique
features that reflect the specific biology of this emerging pathogen.
The data also provide groundwork for the development of im-
proved diagnostic tests that will facilitate understanding of the
pathogenesis, epidemiology, and mode of transmission of this
emerging pathogen. Finally, as a first step toward experimental use
of this genetic information, we identify means to introduce and
express foreign genetic material inM.haemophilum, which should
allow exploitation of this organism as a means to study gene prod-
ucts uniquely shared with M. leprae.
RESULTS AND DISCUSSION
In vitro growth phenotypes.M. haemophilum requires iron sup-
plementation for its growth. We explored the effect of different
iron sources by propagatingM. haemophilum in heme-containing
7H9 liquid medium and then washing and plating the bacteria
onto various solid media. Unable to grow on oleic acid-albumin-
dextrose-catalase (OADC)-enriched Middlebrook 7H10 agar
without other supplements, M. haemophilum grew well on 7H10
medium containing 100 M hemin (Fig. 1A). Growth was also
well-supported on 7H10 agar supplemented with human hemo-
globin and on 5% sheep blood agar. Growth was somewhat less
abundant on chocolate agar (in which blood cells have been lysed
by heating) (Fig. 1A). These data are consistent with prior obser-
vations (2, 5, 26, 27).
Mycobacterium tuberculosis and other mycobacteria produce
siderophores, small iron-chelating compounds, termed mycobac-
tins and carboxymycobactins, which bind and facilitate uptake of
environmental ferric iron (Fe3). In one prior report, several
M. haemophilum clinical isolates failed to grow on Lowenstein-
Jensen (LJ) medium supplemented with mycobactin at 2 g/ml
(28), but earlier studies on one of the same isolates (prior to its
identification as M. haemophilum) reported that mycobactin did
support growth (29). We observed that M. haemophilum failed to
form colonies on 7H10 agar supplemented with 2 g/ml myco-
bactin J (from Mycobacterium avium subsp. paratuberculosis), but
it did form colonies with 100 M hemin (Fig. 1A). We also com-
pared the growth properties ofM. haemophilumwith mc26230, an
M. tuberculosis H37Rv RD1 panCD auxotrophic strain that
FIG 1 M. haemophilum growth is supported by hemin and hemoglobin, but
not by mycobactin or carboxymycobactin. (A) M. haemophilum was plated
onto 7H10 medium without supplement; 7H10 medium supplemented with
100 M hemin, 2 g/ml mycobactin J (MbJ), or 100 M human hemoglobin
(Hg); or 5% sheep blood agar or chocolate agar. Photographs were taken after
~8 weeks of incubation at 30°C. (B) Growth of M. haemophilum, M. tubercu-
losis strain mc26230, or M. tuberculosis strain mc26230 with deletion of the
mbtB gene (mbtB) on 7H10 medium containing 24 g/ml pantothenate
(pan) and without further supplement, or supplemented with the indicated
concentrations of hemin, MbJ, or M. smegmatis carboxymycobactin (cMb).
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requires pantothenate supplementation (7H10-pan) and can be
used under biosafety level 2 (BSL2) containment (30, 31), with
those of a mbtB mutant strain generated in the mc26230 back-
ground which lacks an essential component of the mycobactin
synthesis pathway (32). Whereas mc26230 grew well under all
conditions tested, the mbtB mutant failed to grow on 7H10-pan
but did grow on 7H10-pan supplemented with 100 M hemin,
2 g/ml mycobactin J, and 200 ng/ml M. smegmatis carboxymy-
cobactin (Fig. 1B). In contrast, M. haemophilum was unable to
grow with either mycobactin J or carboxymycobactin supplemen-
tation, although again, growth was abundant on 100 M hemin
(Fig. 1B). These results suggest a defect(s) in the uptake and/or
utilization of siderophore-bound iron by M. haemophilum.
In several experiments, inoculation of M. haemophilum onto
7H10 medium supplemented with 15 mg/ml ferric ammonium
citrate (FAC) resulted in absent or very suboptimal growth (data
not shown). Others have observed growth of M. haemophilum on
LJ medium supplemented with 15 mg/ml FAC but not on 7H10
medium with the same concentration of FAC (28, 33). Con-
versely, although 7H10 supplemented with hemin supports
growth, it has been observed that LJ with hemin does not (27, 28,
33). These findings suggest that interactions occur between par-
ticular iron complexes and other components of the media.
Overview of the M. haemophilum genome. To gain further
insights into its growth requirements, the complete M. haemophi-
lum genome sequence was determined. The genome consists of a
single circular chromosome of 4,235,765 bp with an average GC
content of 63.9% and encodes an estimated 3,964 genes (NCBI
Prokaryotic Genome Annotation Pipeline). Pertinent characteris-
tics of the genome in comparison with other mycobacterial species
are listed in Table S1 in the supplemental material. Functional
assignments using database comparisons were obtained for ap-
proximately two-thirds of coding sequences, with the remainder
encoding hypothetical proteins (Rapid Annotation Using Subsys-
tem Technology, or RAST [National Microbial Pathogen Data
Resource]). Gene numbers referred to in the text are those as-
signed by RAST under Genome ID 1202450.9. A representation of
the M. haemophilum chromosome is shown in Fig. 2, including
the orientation of the coding sequences, percent GC content, and
GC skew.
Mycobactin synthesis: mbt-1 (mbtA-mbtJ) gene cluster. In
M. tuberculosis, the salicylate-based mycobactin siderophores are
synthesized by enzymes encoded in two distinct gene clusters,
mbt-1 (mbtA-mbtJ) and mbt-2 (mbtK-mbtN) (34, 35). One strik-
ing feature of the M. haemophilum genome is the absence of close
homologues of almost all of the 14 genes comprising these two
mycobactin synthesis clusters (Fig. 3A and B). For the mbtA-mbtJ
cluster, close homologues of 7 of the 10 genes—mbtG, mbtF,
mbtE, mbtD, mbtC, mbtB, and mbtA—appear to be missing in
M. haemophilum (Fig. 3A). An open reading frame (ORF) encod-
ing a putative protein with significant homology to MbtH, found
at one end of the mbtA-mbtJ locus in H37Rv, does appear to be
present [with 78% identity to H37Rv MbtH (Rv2377c) over
71 amino acids]. However, the product of this gene may not func-
tion in mycobactin synthesis, as homologues in other bacteria,
such as actinomycetes and a rapid-growing mycobacterium, My-
cobacterium smegmatis, have been implicated in other pathways,
such as synthesis of cell wall glycopeptidolipids (36–38).
For the remainder of the mbt-1 gene cluster, close homologues
of mbtJ and mbtI, found at the opposite end of the H37Rv gene
cluster, are also present in M. haemophilum (Fig. 3A). However,
the M. haemophilum mbtJ and mbtI homologues are in a locus
physically distant from thembtH homologue, separated by greater
than 600 kb. MbtJ is a putative acetyl hydrolase whose precise role
in mycobactin synthesis remains unclear (35). MbtI, the first en-
zyme in the mycobactin synthesis pathway, is a salicylate synthase
(39).M. haemophilum does not possess a full-lengthmbtI gene but
does contain an open reading frame encoding a product with ho-
mology to the C-terminal portion of MbtI (88% identity to the
C-terminal 100 amino acids of the H37Rv MbtI). This region also
shares homology with TrpE (anthranilite synthase, which cata-
lyzes the first committed step in tryptophan biosynthesis) and
other enzymes which act on chorismate in a variety of metabolic
pathways (39). Therefore, this gene might participate in a different
metabolic pathway.
Mycobactin synthesis:mbt-2 (mbtK-mbtN) gene cluster. Al-
though M. tuberculosis mbt-1 encodes enzymes necessary for syn-
thesis of the mycobactin backbone, it lacks genes encoding en-
zymes that attach the fatty acyl chain. These components of the
siderophore biosynthetic machinery lie within the mbt-2 (mbtK-
mbtN) gene cluster (34). The entire mbt-2 gene cluster appears to
be absent inM. haemophilum (Fig. 3B). Together with the absence
of mbtG, mbtF, mbtE, mbtD, mbtC, mbtB, and mbtA homologues,
the absence of all four genes comprising thembt-2 cluster makes it
highly unlikely that M. haemophilum is capable of synthesizing
mycobactin siderophores. Interestingly, the only mycobacterial
species with similarly extensive deletions of the mbt-1 and mbt-2
regions are M. leprae (40) and the recently identified and closely
related M. lepromatosis (41, 42), both of which have genomes
characterized by extreme reductive evolution.
Functional analysis of mycobactin synthesis. To experimen-
tally address production of mycobactin or carboxymycobactin by
M.haemophilum, we cultured the bacteria under iron-replete con-
ditions followed by transfer to iron-limited medium containing
the radiolabeled mycobactin precursor [7-14C]salicylic acid. The
iron-limited medium should, based on data from M. tuberculosis
(43), increase expression of the mycobactin synthesis machinery.
M. tuberculosis mc26230, which has intact mycobactin synthesis,
secretion, and uptake systems, was grown under similar condi-
tions and served as a control. We tested two growth conditions:
chelated 7H9 (see the supplemental text describing further mate-
rials and methods) in the presence and absence of 10 M hemin.
We expected that the latter might afford better growth while still
imposing iron restriction. Cell-associated and secreted sidero-
phores extracted from cell pellets and culture filtrates were ana-
lyzed by thin-layer chromatography (TLC). Because M. haemo-
philum failed to grow as well as mc26230 in the iron-limited
medium, even with the addition of 10M hemin, the two M. hae-
mophilum cultures were pooled for siderophore extraction. TLC
analysis revealed an absence of mycobactin or carboxymycobactin
production by M. haemophilum under the growth conditions
tested, in either the cell pellet or the culture supernatant (Fig. 4).
For mc26230, both mycobactin and carboxymycobactin were
present in the cell pellet, with smaller amounts in the culture su-
pernatant. These findings are the first direct evidence for lack of
mycobactin/carboxymycobactin production by M. haemophilum.
Due to relatively poor growth of M. haemophilum compared with
mc26230 in the iron-limited medium, a significantly smaller cell
mass was analyzed; however, despite equal radioactive label on
material being run on the TLC, there was still a complete absence
Mycobacterium haemophilum Complete Genome Sequence
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of mycobactin and carboxymycobactin detected in the M. haemo-
philum samples, and the only radiolabeled species associated with
the cell pellet was [14C]salicylate. The suboptimal growth of
M. haemophilum in iron-limited medium is, in itself, consistent
with a lack of siderophore production by the strain. The M. hae-
mophilum genome, like that of M. tuberculosis, appears to lack a
gene cluster homologous to that present in the rapid-growing
M. smegmatis which encodes the synthesis of the non-salicylate-
containing peptidic exochelin siderophores (44–46); however, the
possibility that M. haemophilum synthesizes an alternative sidero-
phore is not excluded.
Mycobactin uptake and secretion: IrtA/B andMmpL/MmpS
proteins. Adjacent to the mbt-2 gene cluster in M. tuberculosis
H37Rv are the iron-regulated transporter A (irtA; Rv1348) and
FIG 2 Circular representation of the M. haemophilum chromosome. Concentric rings, numbered from outer to inner rings, show the following: 1, scale (in
megabases) starting at the top center and running clockwise; 2, forward coding sequences (CDS), in dark green; 3, reverse CDS, in light green; 4, GC content
(percentage) as a line plot, with axes from 20% (inner) to 80% (outer), with lines every 15%, where the dark orange background indicates a GC content above
50%; 5, GC skew of genes as a line plot symmetrical about a skew of 1. The plot was generated using the CIRCOS circular genome data visualization program and
the genome sequence as submitted for annotation by RAST.
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irtB (Rv1349) genes, which are cotranscribed (47) and, along with
the mbt-1 and mbt-2 clusters, are part of the IdeR regulon, with
their transcription repressed under iron-replete conditions (43,
48). irtA and irtB appear to encode an ABC transporter which
participates in the uptake and utilization of siderophore-bound
iron and enables growth under iron-deficient conditions (49).
Homologues of irtA and irtB are lacking in M. haemophilum
(Fig. 3B), again similar to M. leprae.
Recently, members of the mycobacterial membrane protein
large (MmpL) and small (MmpS) families have been found to play
a role in the secretion of mycobacterial siderophores (50). M. hae-
mophilum encodes close counterparts of MmpL4 (Mh0573) and
MmpS4 (Mh0574), located immediately adjacent to one another.
However, although there are additional mmpL and mmpS genes,
we were unable to identify equally close homologues of MmpL5
and MmpS5, which contribute to siderophore synthesis and se-
cretion in M. tuberculosis (50). Notably, MmpS4 is also required
for export of cell surface glycopeptidolipids in M. smegmatis (51).
Therefore, M. haemophilum MmpS4/MmpL4 homologues may
participate in transport of substances other than mycobactins.
Heme uptake, utilization, and biosynthesis. Recently, a heme
acquisition system involving a secreted heme-binding protein
(Rv0203) and the transmembrane proteins MmpL11 (Rv0202c)
and MmpL3 (Rv0206c) was identified for M. tuberculosis (52).
M. haemophilum encodes homologues of Rv0203 (Mh0273),
MmpL11 (Mh0272), and MmpL3 (Mh0276), located in close
proximity to one another, similar to their counterparts in H37Rv.
M. haemophilum also encodes a homologue (Mh3902) of the
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M. tuberculosis MhuD (mycobacterial heme utilization, degrader;
Rv3592), which binds to and degrades heme (53). Therefore, our
genome sequence data reveal intact heme uptake and utilization
systems in M. haemophilum, in agreement with the results of the
growth studies reported here. This in contrast to M. leprae, which,
although it encodes homologues of MmpL11 and MmpL3, ap-
pears to lack a counterpart to the secreted heme-binding protein
Rv0203 (40), suggesting a possible deficiency in the scavenging of
heme-iron. M. haemophilum also appears to possess close homo-
logues of M. tuberculosis H37Rv genes that encode putative heme
biosynthetic pathway components (see Table S2 in the supple-
mental material), and again this differs from M. leprae, which is
missing the hemN gene (42), and therefore may be impaired in
heme biosynthesis.
ESX loci including ESX-3. Type VII secretion systems (T7SSs)
encoded within ESX loci permit transport of proteins across the
lipid-rich cell envelope to the cell surface or external environment.
The ESX loci are large gene clusters which code for the ATP-
dependent secretory apparatuses needed to export members of the
6-kDa early secretory antigenic target (ESAT-6)/culture filtrate
protein 10 (CFP-10) protein families (EsxA/EsxB of the ESX-1
region and their paralogues), as well as a number of additional/
associated substrates which remain to be fully defined. M. tuber-
culosis possesses five ESX systems, encoded within gene clusters
designated ESX-1 to ESX-5, several of which play important roles
in M. tuberculosis pathogenesis and intracellular survival (54).
M. haemophilum possesses homologues of all five ESX systems
(see Table S3 in the supplemental material).
The ESX-3 locus of M. haemophilum is of particular interest,
because it has been implicated in iron and zinc homeostasis in
M. tuberculosis (55–57). M. tuberculosis esx-3 expression is regu-
lated by the availability of iron and zinc, under control of both the
IdeR repressor and the zinc uptake regulator Zur/FurB (Rv2359)
(58). ESX-3 is likely necessary for the uptake and/or utilization of
iron bound to mycobactin (57), although involvement in alterna-
tive mycobacterial metal ion uptake processes has also been sug-
gested (59, 60). The absence of genes required for mycobactin
synthesis and mycobactin uptake/export in M. haemophilum
makes a largely intact ESX-3 locus inM. haemophilumnoteworthy
(Fig. 5). Of the 11 ORFs in the M. tuberculosis ESX-3 region, 10
have close homologues in the corresponding region of M. haemo-
philum, including genes encoding both EsxG and EsxH, which are
believed to be secreted as a heterodimeric complex (57, 61), sim-
ilar to the EsxA-EsxB secreted effectors of the ESX-1 region.
All ESX loci with the exception of the smallest and most ar-
chaic, ESX-4, possess a pe-ppe gene pair adjacent to the esx gene
pair (54); these are named for the conserved proline-glutamic acid
(PE) and proline-proline-glutamic acid (PPE) residues found
near the N termini of the encoded proteins. The only gene which is
absent from its expected location within the ESX-3 region of
M. haemophilum is ppe4 (Rv0286), the ppe component of the pe-
ppe pair present within the M. tuberculosis H37Rv ESX-3 locus
(Fig. 5). The significance of this absence with regard to the iron-
dependent growth phenotype of the organism and the inability of
mycobactin to support growth (Fig. 1A and B) is unclear, because
the functions of the pe and ppe gene families remain largely ob-
scure. It is possible that this deficiency is compensated by ppe
homologues encoded elsewhere in the genome. Notably, M. hae-
mophilum does possess a ppe gene immediately upstream of the
ESX-3 locus.
Although the M. haemophilum genome shares with M. tuber-
culosis the presence of five ESX loci, there are some differences
from the corresponding M. tuberculosis ESX regions. The primary
difference is that several of the pe and ppe genes are absent from
M. haemophilum, such as an absent pe35 homologue within the
ESX-1 locus and an absent ppe4 in the ESX-3 locus, although some
of the regions differ in other respects as well (see Table S3 in the
supplemental material). For ESX-2, homologues of all 12 of the
corresponding M. tuberculosis genes are present, but the region is
discontinuous, similar to findings for M. avium subsp. paratuber-
culosis (62).
Genes present inM.haemophilumbut absent fromM. tuber-
culosisH37Rv that may be related to iron acquisition. Compar-
ison of the M. haemophilum genome with other mycobacterial
species revealed a number of genes present inM.haemophilum but
absent from M. tuberculosis H37Rv. These included several genes
with potential roles in iron acquisition. One, Mh1776, is anno-
tated as ferrous iron transport protein B (feoB) and encodes a
protein with significant homology to an integral component of the
Feo inner membrane transport system, which functions in the
uptake of ferrous (Fe2) iron (63, 64). Although this system has
been best studied in enteric Gram-negative bacteria such as Esch-
erichia coli and Salmonella species (65, 66), genes encoding the Feo
system have been identified in more than 40% of sequenced bac-
terial genomes (64).
In E. coli, the Feo system contains three genes encoded in the
locus feoABC; although in other bacterial genomes, feoC is often
absent (64). This is the situation for M. haemophilum, which con-
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FIG 4 M. haemophilum does not produce mycobactin. Synthesis and release
of mycobactin was assessed by culturing M. tuberculosis strain mc26230 or
M. haemophilum in iron-deficient media, conditions that induced mycobactin
synthesis for M. tuberculosis. [14C]salicylate was added to cultures to label
newly synthesized mycobactin, and extracts of bacterial pellets and culture
supernatants were analyzed by TLC by loading equal activity (counts per min-
ute). Lane 1, mc26230 cell pellet; lane 2, M. haemophilum cell pellet; lane 3,
mc26230 supernatant; lane 4, M. haemophilum supernatant; lane 5,
[14C]salicylate. Indicated are the expected locations of mycobactin (Mb) and
carboxymycobactin (cMb) from M. smegmatis, based on migration of purified
nonradioactive standards (data not shown).
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tains adjacent feoA (Mh1777) and feoB (Mh1776) genes, but has
no obvious feoC paralogue. Ferrous iron is thought to be trans-
ported across the cytoplasmic membrane by the GTP-dependent
permease FeoB (67). The small hydrophilic FeoA protein appears
to interact with FeoB and to be required for transport (68). The
presence of FeoA and FeoB suggests that M. haemophilum may
encounter conditions (anaerobic and/or acidic) in its in vivo niche
that increase the availability of ferrous iron, or perhaps that the
bacterium is capable of reducing extracellular ferric ions to pro-
mote uptake by this system. Although absent in M. tuberculosis
and M. leprae, BLAST analysis identifies homologues of FeoA and
FeoB in a number of nontuberculous mycobacteria, including
M. kansasii, M. marinum, M. genavense, and M. xenopi.
M. haemophilum also possesses a second natural resistance-
associated macrophage protein (Nramp) family member. Nramps
were initially identified in eukaryotes as integral membrane pro-
teins that function as pH-dependent high-affinity divalent metal
ion transporters (69–71). Many bacteria also possess Nramp fam-
ily members (72, 73), including M. tuberculosis, which has a single
homologue (74–76). This is in contrast to M. leprae which, even
with its small genome size, bears two copies of a mntH/nramp
homologue (40); our sequencing results demonstrated that this is
also true for M. haemophilum (Mh0166 and Mh3510), which oc-
cupies a somewhat similar in vivo niche. These conserved Nramp
homologues are candidate iron uptake factors.
Iron uptake in bacteria is both critical and complex, character-
ized by the presence of multiple transport systems which may be
utilized under different environmental conditions (77). In addi-
tion to the systems described above, it is likely that M. haemophi-
lum encodes additional gene products involved in iron uptake.
For instance, M. haemophilum encodes a locus (Mh0534-
Mh0536) with homology to ATP-binding cassette (ABC) trans-
port systems of the iron/siderophore/heme/vitamin B12 type
(78), including putative permease (Mh0536) and ATP-binding
(Mh0535) components as well as a putative substrate binding pro-
tein (Mh0534) homologous to proteins that play roles in iron
uptake in other bacteria. Interestingly, this locus is absent in both
M. tuberculosis and M. leprae. Future studies examining growth in
the presence of ferrous iron and transcriptional responses of
M. haemophilum under iron-replete versus iron-limited condi-
tions and aerobic versus hypoxic conditions may help clarify the
contributions of the gene products described above and identify
additional genes involved in novel iron uptake pathways. Ulti-
mately, it may also be informative to compare in vitro gene expres-
sion profiles to those obtained during intracellular and in vivo
growth, to help elucidate mechanisms of iron acquisition in the
context of infection.
Evolutionary relationships of M. haemophilum. Previous
phylogenetic analyses based on limited available sequence data,
such as rpoB gene comparisons, have suggested a close evolution-
ary relationship between M. haemophilum and M. leprae (79, 80).
Our complete genome sequence data confirm the closeness of
this relationship. A phylogenetic tree constructed by whole-
chromosome comparison to 14 selected mycobacterial genomes
using the BLAST algorithm revealed the closest neighbors to
M. haemophilum DSM 44634/ATCC 29548 to be the M. leprae
strains TN and B4923 and the recently identified M. lepromatosis
(Fig. 6). This is also consistent with the genetic similarities detailed
above and with analyses of fatty acid compositions and phenolic
glycolipid contents of the organisms (81–83). However, at ~4.23
Mb, the genome of M. haemophilum is substantially larger than
the ~3.27-Mb genomes of M. leprae and M. lepromatosis. The lat-
ter have both undergone extensive pseudogenization, of about
approximately 50% of the genome (40, 42), while for M. haemo-
philum pseudogenes account for only ~7% of the total (NCBI
Prokaryotic Genome Annotation Pipeline) (see Table S1 in the
supplemental material). This suggests that the described reductive
evolution ofM. leprae andM. lepromatosiswas not shared with the
pe5
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common ancestor, but instead began after divergence of M. hae-
mophilum from the other two species.
Expression of foreign genes in M. haemophilum. Exploiting
the genome sequence of and developing M. haemophilum into a
model system could expand our understanding of its pathophys-
iology and allow new insights into M. leprae, which cannot be
cultivated in vitro. Therefore, we explored whether we could
transform M. haemophilum by electroporation, using protocols
established for other slow-growing mycobacteria. Transforma-
tions with “empty vector” plasmid DNAs demonstrated abundant
recovery of colonies when we used 100 g/ml kanamycin (for
pMV261-kan and pMV361-kan) or 100 g/ml hygromycin (for
pMV361-hyg) as selection agents (Fig. 7A). The no-DNA control
transformations yielded no colonies at ~3 weeks of incubation,
although with extended incubation small colonies appeared on
the kanamycin-supplemented plates, indicating that higher anti-
biotic concentrations may be preferable. We noted the attB site
(integration site for the pMV361 vectors) of M. haemophilum was
identical to that of M. smegmatis. Integration of pMV361-kan and
pMV361-hyg was confirmed by PCR across the attB locus and
sequencing of products (data not shown). We also transformed
M. haemophilum with an episomal plasmid expressing the tdTo-
mato fluorescent protein under control of the M. marinum G13
promoter, a strong constitutive mycobacterial promoter that
yields high expression levels (84). We found tdTomato to be very
highly expressed, as indicated by the intense pink color of the
colonies, which deepened further with extended incubation
(Fig. 7A). Fluorescence of transformants was confirmed by mi-
croscopy (Fig. 7B), revealing a characteristic mycobacterial cord-
ing. These data provide the first demonstration thatM. haemophi-
lum can be genetically manipulated with molecular tools
established for other mycobacterial species and establish a foun-
dation upon which the sequence data obtained here can be ex-
ploited to study this unique human pathogen.
Conclusions. Fundamental to understanding M. haemophi-
lum as a pathogen are defining the basis for its unique growth
requirements and its relationships to other mycobacteria. Our
sequence and experimental data provide insight into the require-
ment of M. haemophilum for specific iron supplements, which
may contribute to its modest virulence in immunocompetent in-
dividuals. The sequence data provided here may also facilitate
diagnostics. Current molecular diagnostic approaches for detec-
tion of M. haemophilum in clinical samples utilize PCR-based
methods (85, 86) and rely on very limited sequence informa-
tion. Because there may be genetic diversity among M. haemo-
philum isolates from different geographic areas (87–89), diag-
nostics might be improved by designing additional PCR-based,
hybridization-based, and antigen-based tests for M. haemophilum
by using information derived from the complete genome se-
quence. This information may also enable improved epidemio-
logical and environmental testing, expanding the molecular tools
FIG 6 Phylogenetic tree of selected mycobacterial species. A phylogenetic tree was constructed for 15 mycobacterial genomes, including M. haemophilum, and
one outgroup genome as described in Materials and Methods. The scale (0.025) indicates substitutions per aligned position.
FIG 7 Successful transformation of M. haemophilum. (A) M. haemophi-
lum was transformed with an integrating vector conferring hygromycin
resistance (pMV361-hyg), an episomal vector conferring kanamycin resis-
tance (pMV261-kan), an integrating vector conferring kanamycin resistance
(pMV361-kan), or an episomal vector conferring kanamycin resistance and
expressing the red fluorescent protein tdTomato from the M. marinum G13
promoter (pYUB1169). Colonies were photographed after 24 days of incuba-
tion at 30°C, while colonies harboring the tdTomato-expressing construct
were photographed again at 33 days postincubation, to demonstrate intensi-
fication of the pink color. No-DNA controls demonstrating sensitivity of
M. haemophilum to kanamycin and hygromycin at the indicated concentra-
tions are also shown. In addition to antibiotic supplements, all plates also
contained 100 M hemin. (B) M. haemophilum transformed with the tdTo-
mato fluoresce red. Images were obtained with a Nikon Eclipse TiE micro-
scope using a CFI Plan Apo VC 100/1.40 numerical aperture objective and a
BrightLine Ex56240 filter set. The fluorescent image is shown on the left and a
differential interference contrast image is on the right.
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available to evaluate diversity. Our findings also demonstrate a
close genetic relationship betweenM. haemophilum andM. leprae,
the latter an important human pathogen that cannot be propa-
gated in vitro. The successful transformation of M. haemophilum
coupled with the genomic sequence will facilitate studies to eluci-
date the features that contribute to the pathogenic properties of
M. haemophilum and allow its use as a surrogate to functionally
characterize gene products uniquely shared by M. haemophilum
and M. leprae.
MATERIALS AND METHODS
Bacterial strains. The Mycobacterium haemophilum type strain (DSM
44634; ATCC 29548) was cultured at 30°C in Middlebrook 7H9 broth
supplemented with 0.2% glycerol, 10% OADC enrichment (Becton,
Dickinson), 0.05% tyloxapol or Tween 80, and 100 M hemin (bovine
[Sigma]; 7H9-hemin) or as described above. Comparative growth studies
utilized mc26230, a RD1 panCD derivative of M. tuberculosis H37Rv
which is approved for use in BSL2 facilities at the Albert Einstein College
of Medicine (31), and an mbtB deletion mutant in the mc26230 back-
ground (see Text S1 in the supplemental material for further details on
our materials and methods). Media for growth of mc26230 and mc26230
mbtB were supplemented with 24 g/ml D-pantothenate (Sigma).
Genome sequencing, assembly, and annotation. Genomic DNA iso-
lated from cultures of M. haemophilum by a cetyltrimethylammonium
bromide-chloroform-based method (90) was sequenced by the Epig-
enomics Shared Facility (ESF) at the Albert Einstein College of Medicine,
using MiSeq (Illumina), and at the Department of Genetics and Genomic
Sciences, Icahn School of Medicine at Mount Sinai, using PacBio meth-
odologies. Details of genome sequencing, assembly, and annotation are
provided in Text S1 in the supplemental material.
Phylogenetic analysis. A phylogenetic tree was constructed for 15
mycobacterial genomes, including that of M. haemophilum and one out-
group genome. Further details concerning our materials and methods are
provided in Text S1 in the supplemental material.
Protocol for plating on variousmedia types.M. haemophilum bacte-
ria cultured in 7H9-hemin were pelleted by centrifugation and washed in
phosphate-buffered saline (PBS) containing 0.05% tyloxapol or 0.05%
Tween 80 (PBS-T), following which equal inocula were plated onto the
various media being tested. Details are provided in the Text S1 in the
supplemental material.
Transformation of M. haemophilum. M. haemophilum transforma-
tion was performed according to methods developed for M. tuberculosis
(90), except M. haemophilum was grown at 30°C. See Text S1 in the sup-
plemental material for details.
Examination of mycobactin and carboxymycobactin synthesis and
secretionbasedonuse of a radiolabeledprecursor.M.haemophilum and
strain mc26230 were cultured in 7H9 medium without hemin in order to
deplete iron stores, following which bacteria were transferred to iron-
limited 7H9 medium (treated overnight with the iron chelator Chelex-
100; details are provided in Text S1 in the supplemental material). Bacte-
ria were inoculated at a starting optical density at 600 nm of 0.3 in 5 ml of
medium in the presence of 1 Ci/ml [7-14C]salicylic acid (PerkinElmer)
and grown with shaking for 20 days at 37°C for mc26230 and at 30°C for
M. haemophilum. For M. haemophilum, cultures were prepared in dupli-
cate, one lacking iron sources and one containing 10 M hemin. Sidero-
phores were extracted according to the method of Wells et al. (50) (see
Text S1 for further details regarding our materials and methods). Extracts
from cell pellets and culture supernatants were resuspended in chloro-
form and spotted on TLC silica gel 60F254 plates, with samples normalized
based on equivalent radioactivity levels.
Nucleotide sequence accession numbers. Sequence data were depos-
ited in the NCBI repository under BioProject PRJNA171821 (Mycobacte-
rium haemophilum DSM 44634, ATCC 29548). The complete genome
sequence is available under accession number CP011883. Short Illu-
mina reads, Illumina mate-pair reads, Pacific Biosciences SMRT reads,
and Sanger sequencing information were deposited in the NCBI Se-
quence Read Archive (SRA) under accession numbers SRX1059681,
SRX1059688, SRX1059690, and SRX1059710, respectively. Genome an-
notations were deposited on the RAST website (http://rast.nmpdr.org/)
(91, 92), first under Genome ID 1202450.3 and later updated to begin the
sequence at dnaA, under Genome ID 1202450.9. The M. haemophilum
gene numbers referenced in the text are those assigned based on the RAST
annotation, Genome ID 1202450.9.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org/
lookup/suppl/doi:10.1128/mBio.01313-15/-/DCSupplemental.
Text S1, DOCX file, 0.1 MB.
Table S1, DOCX file, 0.03 MB.
Table S2, DOCX file, 0.02 MB.
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